<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03195452</url>
  </required_header>
  <id_info>
    <org_study_id>RC16_0317</org_study_id>
    <nct_id>NCT03195452</nct_id>
  </id_info>
  <brief_title>QDISS Stud: QD Isentress as Switch Strategy in Virologically Suppressed HIV-1 Infected-Patient</brief_title>
  <acronym>QDISS</acronym>
  <official_title>QD Isentress as Switch Strategy in Virologically Suppressed HIV-1 Infected-Patient</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Raltegravir (RAL) is a very effective antiretroviral drug with a favorable long term&#xD;
      tolerability. RAL offers many advantages such as lack of drug-drug interactions, a good&#xD;
      safety profile particularly on lipids, inflammation and bone parameters. Ral can be an very&#xD;
      interesting for patient with comorbidities and comedications, intolerance or toxicities with&#xD;
      their current ARV treatment. However its current formulation of one tablet of 400mg twice a&#xD;
      day coul not suit many patients.&#xD;
&#xD;
      A new once-a-day formulation of RAL has been developed, with two tablets of 600 mg QD.&#xD;
      Pharmacokinetic study in healthy volunteers has shown that this dosing provides increased RAL&#xD;
      exposure compared to the standard formulation of 400 mg given twice a day.&#xD;
&#xD;
      The objective of this study is to evaluate the maintain of virologic suppression with&#xD;
      raltegravir 600mg 2 tablets qd as part of a triple antiretroviral regimen in virologically&#xD;
      controlled patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 8, 2017</start_date>
  <completion_date type="Actual">May 6, 2020</completion_date>
  <primary_completion_date type="Actual">October 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of copie/ml plasma HIV - RNA</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Score evaluation of patient satisfaction</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score evaluation of patient quality of life with PROQOL-HIV questionnaires</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score evaluation of adherence</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patient who have a viral load &lt; 50 copies/ml</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of discontinuation of Raltegravir</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of treatment failure</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of genotype resistance mutations</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Virus-HIV</condition>
  <arm_group>
    <arm_group_label>Raltegravir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>antiretroviral tritherapy: Raltegravir 600 mg tablet orally (2 tablets QD) and 2 Nucleoside/Nucleotide reverse transcriptase inhibitor (NRTI)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir and 2 Nucleoside/Nucleotide reverse transcriptase inhibitor (NRTI)</intervention_name>
    <description>All virologically suppressed</description>
    <arm_group_label>Raltegravir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults of both gender ≥ 18 years&#xD;
&#xD;
          -  Signed informed consent form&#xD;
&#xD;
          -  Documented HIV-1 infection&#xD;
&#xD;
          -  Stable antiretroviral therapy for ≥ 6 months consisting of 2 NRTIs (TDF/FTC or ABC/3TC&#xD;
             )+ a 3rd agent either as a once or twice daily regimen, unless there is intolerance&#xD;
             requiring change of therapy. In this situation of intolerance, patient with less than&#xD;
             6 months of current antiretroviral therapy will be allowed in the study.&#xD;
&#xD;
        As soon as TAF/FTC will be available in France, patients receiving TAF/FTC + 3rd agent&#xD;
        could be enrolled.&#xD;
&#xD;
        Switch of TDF/FTC to TAF/FTC will be authorized as long as the change has occurred for more&#xD;
        than 3 months prior to the screening visit. Such switch will be also allowed during the&#xD;
        study, and, unless urgently needed, after the W24 visit.&#xD;
&#xD;
        Patients on stable raltegravir 400 mg 1 tablet twice daily plus 2 NRTI can be enrolled;&#xD;
        number of these patients will be limited to 33% of the total cohort.&#xD;
&#xD;
          -  Indication to current change antiretroviral therapy for at least one of the following&#xD;
             reasons :&#xD;
&#xD;
               1. Intolerance or prevention of toxicity&#xD;
&#xD;
               2. Presence of a comorbid condition justifying change of the 3rd agent&#xD;
&#xD;
               3. Management of drug-drug-interaction&#xD;
&#xD;
               4. Patient's request, including switch to simplify or to improve convenience&#xD;
&#xD;
          -  No prior virological failure on integrase-containing antiretroviral therapy or&#xD;
             NNRTI-containing antiretroviral therapy or NRTI only-therapy&#xD;
&#xD;
          -  HIV-1 RNA &lt; 50 c/mL for ≥ 6 months. However, a single HIV-1 RNA ≥ 50 copies/mL and &lt;&#xD;
             200 copies/mL with a subsequent HIV-1 RNA &lt; 50 c/mL in the past 6 months is allowed.&#xD;
&#xD;
          -  AST and ALT &lt; 5 times the upper limit of normal&#xD;
&#xD;
          -  Estimated glomerular filtration rate by MDRD equation &gt;= 50 mL/min&#xD;
&#xD;
          -  Hemoglobin &gt; 8 g/dL&#xD;
&#xD;
          -  Platelet count &gt; 50 0000/mm3&#xD;
&#xD;
          -  For women of childbearing potential: negative serum test for pregnancy and acceptance&#xD;
             to use contraceptive methods&#xD;
&#xD;
          -  Affiliation to a French Social Security program.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HIV-2 co-infection&#xD;
&#xD;
          -  Concomitant treatments contra-indicated with raltegravir&#xD;
&#xD;
          -  Patients receiving raltegravir 400mg, 2 tablets in one daily intake&#xD;
&#xD;
          -  Patients with prior virological failure on NRTI+PI/r based regimen can be enrolled as&#xD;
             long as historical plasma genotype and/or screening DNA genotype demonstrate absence&#xD;
             of resistance or possible resistance to any drug. Subjects with previous failure to&#xD;
             any other antiretroviral regimen cannot be enrolled.&#xD;
&#xD;
          -  Presence of possible resistance or resistance to any nucleoside reverse transcriptase&#xD;
             inhibitor or integrase inhibitor on a historical plasma genotype.&#xD;
&#xD;
          -  Presence of possible resistance or resistance to any non- nucleoside reverse&#xD;
             transcriptase inhibitor on a historical plasma genotype, with the exception of&#xD;
             polymorphic mutations E138A/G/K/Q/R/S and V179D in patients naïve to NNRTI.&#xD;
&#xD;
          -  Presence of resistance to any PI on a historical plasma genotype&#xD;
&#xD;
        In case were historical plasma genotype being not available or incomplete, resistance&#xD;
        genotype will be performed on DNA at screening visit. Full treatment and cumulative&#xD;
        resistance genotype history will have to be provided, at screening, to the principal&#xD;
        investigator to approve any inclusion.&#xD;
&#xD;
          -  For HCV co-infected patients, if specific treatment for hepatitis is required during&#xD;
             the trial duration, such HCV therapy should be compatible with the ARV combination and&#xD;
             only started after the W24 visit.&#xD;
&#xD;
          -  HBV infection, in the absence of treatment with TDF or TAF&#xD;
&#xD;
          -  Severe associated diseases requiring specific treatment, such as curative treatment of&#xD;
             acute opportunistic infection&#xD;
&#xD;
          -  Treatment with interferon, interleukin or any immunotherapeutic agent or chemotherapy&#xD;
&#xD;
          -  Cancer diagnosis in the past 3 years with the exception of Kaposi sarcoma&#xD;
&#xD;
          -  Subjects participating in another clinical trial evaluating therapies and having an&#xD;
             exclusion period that is still ongoing during the screening phase&#xD;
&#xD;
          -  Any condition which might compromise the safety of treatment and/or patient's&#xD;
             adherence to trial procedures&#xD;
&#xD;
          -  Person under guardianship, trusteeship or deprived of freedom by a judicial or&#xD;
             administrative decision&#xD;
&#xD;
          -  Difficulty in terms of follow-up (vacation, job transfer, geographical distance, lack&#xD;
             of motivation)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU De Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de la Roche Sur Yon</name>
      <address>
        <city>la Roche Sur Yon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH du Mans</name>
      <address>
        <city>Le Mans</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU of NANTES</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR orléans</name>
      <address>
        <city>Orléans</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Bichat</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHu hotel dieu</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU la pitié</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Avicenne</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Necker</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital St Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Reims</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Tourcoing</name>
      <address>
        <city>Tourcoing</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 29, 2017</study_first_submitted>
  <study_first_submitted_qc>June 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2017</study_first_posted>
  <last_update_submitted>May 15, 2020</last_update_submitted>
  <last_update_submitted_qc>May 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Antiretrovirals</keyword>
  <keyword>Raltegravir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

